| Autor: |
Schürks, M., Kurth, T., Stude, P., Rimmbach, C., De Jesus, J., Jonjic, M., Diener, H.-C., Rosskopf, D. |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology & Therapeutics; Oct2007, Vol. 82 Issue 4, p396-401, 6p, 4 Charts |
| Abstrakt: |
Only about 70% of migraine and cluster headache (CH) patients report significant treatment responses to triptans, which are agonists at 5-HT1B/D receptors belonging to the family of G protein-coupled receptors. We analyzed whether a common polymorphism in the gene for the G protein β3 subunit (GNB3 C825T) modulates responder rates to triptans among a cohort of 231 unrelated Caucasian CH patients. A total of 180 CH patients used triptans, of whom 71.1% reported treatment success. The adjusted odds ratio for treatment response to triptans for heterozygous carriers of the GNB3 825T allele was 2.96 (95% confidence interval 1.34–6.56; P=0.0074) vs carriers of the 825CC genotype. The GNB3 genotype status did not affect responses to other acute and preventive therapeutic regimes including oxygen, verapamil, and corticosteroids, i.e., drugs not directly affecting G proteins. We conclude that pain relief by triptans is significantly modulated by a common genetic GNB3 variant.Clinical Pharmacology & Therapeutics (2007) 82, 396–401; doi:10.1038/sj.clpt.6100159; published online 14 March 2007 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text